Skip to content

Comparison of the half-effective doses of oliceridine for inhibiting gastroscopy insertion reaction in patients with different BMI

Comparison of the half-effective doses of oliceridine for inhibiting gastroscopy insertion reaction in patients with different BMI

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600126062
Enrollment
Unknown
Registered
2026-06-03
Start date
2026-06-08
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless gastroscopy

Interventions

Normal group:Patients were divided into 3 groups based on BMI: normal weight group (18.5 kg/m^2 grade 1 during scope insertion), increase the dose by one gradient for the next patient
conversely, decrease the dose by one gradient. The sequence continued until 8 positive-negative reversal points were achieved.
Super-reconstituted group:Patients were divided into 3 groups based on BMI: overweight group (24 kg/m^2 grade 1 during scope insertion), increase the dose by one gradient for the next patient
Obese group:Patients were divided into 3 groups based on BMI: obese group (28 kg/m^2 <= BMI < 32.5 kg/m^2). A modified Dixon sequential meth

Sponsors

No. 109, Longmian Avenue, Jiangning District, Nanjing City, Jiangsu Province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing elective painless gastroscopy; 2. aged 18-64 years; 3. male or female; 4. 18<=BMI<35kg/m^2; 5. American Society of Anesthesiologists (ASA) anesthesia risk classification I-II.

Exclusion criteria

Exclusion criteria: 1. Gastrointestinal obstruction; 2. Recent upper respiratory tract infection; 3. History of allergy to study drug; 4. Severe cardiopulmonary disease; 5. Severe impairment of liver and kidney function; 6. Obstructive sleep apnea syndrome; 7. Narrowing or surgical history of the upper and middle esophagus; 8. Poorly controlled hypertension, diabetes.

Design outcomes

Primary

MeasureTime frame
ED50;

Countries

China

Contacts

Public ContactLi Yuhong

Sir Run Run Hospital Affiliated to Nanjing Medical University

961145584@qq.com+86 152 9836 1602

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026